



EMA/122364/2021

Leganto

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
WS/2000	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.b - Introduction of, or change(s) to, the	11/02/2021	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required				
WS/1963	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	14/01/2021		SmPC and PL	
IA/0034	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	08/12/2020	n/a		
PSUSA/2667/202002	Periodic Safety Update EU Single assessment - rotigotine	01/10/2020	n/a		PRAC Recommendation - maintenance
WS/1689	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	16/01/2020	29/01/2021	SmPC and PL	

WS/1602/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS</p>	04/07/2019	n/a		
IG/1072	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	28/02/2019	n/a		
WS/1381	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of section 4.8 of the SmPC in order to add an adverse drug reaction: Dropped Head Syndrome based on new pharmacovigilance data; The Package Leaflet is updated accordingly.</p> <p>In addition, the Worksharing applicant (WSA) took the opportunity to correct some discrepancies found within the PIL of Greece, Cyprus and Romania and to update the Neupro Annex A in alignment with Leganto Annex A for the description of the multipack size.</p>	07/06/2018	11/04/2019	SmPC and PL	

	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				
IAIN/0028	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	24/04/2018	11/04/2019	Annex II and PL	
T/0026	Transfer of Marketing Authorisation	12/12/2017	18/01/2018	SmPC, Labelling and PL	
PSUSA/2667/ 201702	Periodic Safety Update EU Single assessment - rotigotine	12/10/2017	08/12/2017		Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUSA/2667/201702.
WS/1238/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e.z - Change in container closure system of the Finished Product - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	09/11/2017	18/01/2018	SmPC, Labelling and PL	
N/0023	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	29/06/2017	08/12/2017	PL	
WS/0950	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.	10/11/2016	n/a		

	B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions				
IG/0710	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	26/07/2016	n/a		
WS/0886/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.a.3.b.5 - Changes in the composition (excipients) of the finished product - Other excipients - Change that is supported by a bioequivalence study</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold</p> <p>B.II.b.5.a - Change to in-process tests or limits</p>	25/02/2016	16/02/2017	SmPC, Labelling and PL	

<p>applied during the manufacture of the finished product</p> <ul style="list-style-type: none"> - Tightening of in-process limits <p>B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product</p> <ul style="list-style-type: none"> - Addition of a new test(s) and limits <p>B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation</p> <p>B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation</p> <p>B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation</p> <p>B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits</p> <p>B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure</p> <p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p> <p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p> <p>B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter</p> <p>B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range</p> <p>B.II.d.1.z - Change in the specification parameters</p>				
---	--	--	--	--

<p>and/or limits of the finished product - Other variation B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including</p>				
---	--	--	--	--

	<p>replacement or addition)</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p> <p>B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)</p> <p>B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product</p>				
R/0019	Renewal of the marketing authorisation.	19/11/2015	14/01/2016	SmPC, Annex II, Labelling and PL	Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Leganto continues to be favourable. The CHMP is of the opinion that the renewal can be granted with unlimited validity
WS/0751/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Submission of two final reports of studies which investigated the potential risk of cardiovalvular fibrosis in Parkinson's disease patients treated with</p>	25/06/2015	n/a		

	<p>rotigotine. The RMP version 4 is updated accordingly.</p> <p>C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority</p> <p>C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority</p>				
WS/0684	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of section 4.8 of the SmPC to include the adverse event "dopamine dysregulation syndrome". The package leaflet is amended accordingly.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	26/02/2015	14/01/2016	SmPC and PL	A safety signal assessment to evaluate the association of dopamine dysregulation syndrome (DDS) with rotigotine was recently conducted and this safety signal was confirmed. As a result, the rotigotine company core data sheet (CCDS) was updated to include DDS as an additional AE term under undesirable effects. Consequently, the product information has been updated in this type II variation to include DDS.
WS/0674	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of sections 4.2 and 5.2 of the SmPC to amend information about the paediatric population following the conduct of a dose-escalation Study SP1004 in paediatric patients with Idiopathic Restless Legs Syndrome. Section 4.2 is updated in line with the current QRD template for paediatric information. The MAH also took the opportunity to make minor editorial</p>	26/02/2015	14/01/2016	SmPC and PL	

	<p>corrections in the package leaflet.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>				
IG/0520/G	<p>This was an application for a group of variations.</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place</p>	26/01/2015	n/a		
WS/0659	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>To include an alternative manufacturer of the starting material for the active substance.</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p>	18/12/2014	n/a		To include an alternative manufacturer of the starting material for the active substance.

PSUV/0013	Periodic Safety Update	25/09/2014	21/11/2014	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0013.
WS/0450	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	23/01/2014	21/11/2014	SmPC and PL	<p>The present Type II variation application was meant to update the rotigotine EU Product Information (Summary of Product Characteristics [SmPC] and Patient Information Leaflet [PIL]) to include the changes made to the CCDS as a result of review of clinical and post-marketing data.</p> <p>CHMP requested that the terms 'delusion' and 'delirium' be kept in the warning on abnormal thinking and behaviour, and agreed on the changes proposed regarding peripheral oedema, agitation, impulse control disorders and hypersensitivity reactions.</p> <p>Additionally, editorial and orthographical changes have been made in SmPC sections 4.2, 4.4, 4.8 and 5.1 to facilitate reading.</p> <p>The patient leaflet was amended to align with the SmPC changes outlined above.</p>
WS/0385	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of the PI in line with QRD template 9.0.</p> <p>C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation</p>	27/06/2013	31/07/2013	SmPC, Annex II, Labelling and PL	All parts of the product information were brought in line with QRD template 9.0 including standard text to encourage reporting of adverse reactions by healthcare professionals and patients as well as the update of Annex II to reflect the requirement of PSUR submissions in line with the EURD list and of RMP updates.
WS/0394	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.	27/06/2013	n/a		

	<p>Change to the specification limits of the finished product.</p> <p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p>				
IG/0222	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	16/11/2012	n/a		
WS/0293	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of section 5.1 of the SmPC in order to include summary descriptions of two clinical studies in relation to the use of equipotent doses for rotigotine as compared to ropinirole and other dopamine agonists as well as to amend the wording on the comparability of efficacy of rotigotine versus ropinirole, as observed in one of the pivotal trials.</p> <p>C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data</p>	15/11/2012	18/12/2012	SmPC	The update is based on data from two clinical trials, supported by three additional studies, investigating the efficacy and safety of rotigotine patches in equipotent doses to the oral dopamine agonists ropinirole, pramipexole and cabergoline. One of the studies indicated that effective control of Parkinson's disease symptoms can be achieved when switching from an oral dopamine agonists to rotigotine patch. Section 5.1 of the SmPC was updated to reflect relevant information on these two studies and to correct a statement on the comparability of efficacy of rotigotine and ropinirole observed in a previous pivotal trial.
WS/0286/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of sections 4.4 and 4.8 of the SmPC in order to update the safety information in relation to binge</p>	15/11/2012	18/12/2012	SmPC and PL	Following a request from the CHMP based on the review of PSUR data, aggression/aggressive behaviour as well as binge eating and compulsive eating were included as rare adverse reactions in the product information. Furthermore, based on a recent review of the available post-marketing data in relation to the risk of development of impulse control

	<p>eating and aggression and to implement a class labelling for impulse control disorders. The Package Leaflet was updated in accordance.</p> <p>C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH</p> <p>C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH</p>				<p>disorders when using medicinal products containing levodopa, dopamine agonists and/or Catechol-O-methyltransferase (COMT) inhibitors, the CHMP/PhVWP recommended a class labelling to update and harmonise the product information of all products concerned. To this end, the product information was updated to reflect related behavioural symptoms including compulsive spending or buying, binge eating and compulsive eating and that the adverse reaction can occur irrespective of the indication and at normal doses. Regular monitoring of patients and a careful review of treatment, if symptoms occur, is recommended. The Package Leaflet was updated in accordance and advice for the patient's family and carers was provided.</p>
WS/0226/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <ul style="list-style-type: none"> - to change the quantitative composition of the rotigotine transdermal patches for some excipients included in the drug containing self adhesive mass of the reformulated product. - to update the manufacturing process for the reformulated product. - to replace the details of the current approved batch sizes. - to add an editorial update to replace details formerly approved for a theoretical batch size. - to remove some of the current approved details to align with current manufacturing practice. 	19/07/2012	30/08/2012	SmPC, Annex II, Labelling and PL	

- to tighten some specification limits.
- to update the specification for compendial excipients to include USP and/or USP-NF testing in addition to current approved Ph.Eur.
- to update some of non-compendial excipients.
- to update some of the release and shelf-life specification of the finished product.
- to tighten some of the shelf-life specification limit.
- to tighten some of the release and shelf life specification limits.
- to delete some of testing from the release and shelf-life specifications.
- to update the release and shelf-life specification for drug release.
- to change the some test procedures.
- to change some the analytical procedures.
- to change the storage conditions for the reformulated, room temperature stable product from "store in a refrigerator (2°C-8°C)" to "do not store above 25°C".
- to extend the shelf life of the finished product from 18 months to 24 months.

B.II.a.3.b.5 - Changes in the composition (excipients) of the finished product - Other excipients - Change that is supported by a bioequivalence study

B.II.b.3.b - Change in the manufacturing process of the finished product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product

B.II.b.4.z - Change in the batch size (including batch

<p>size ranges) of the finished product - Other variation</p> <p>B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits</p> <p>B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits</p> <p>B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits</p> <p>B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new tests and limits</p> <p>B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new tests and limits</p> <p>B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test</p> <p>B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test</p> <p>B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test</p> <p>B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test</p> <p>B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation</p> <p>B.II.b.5.z - Change to in-process tests or limits applied</p>				
--	--	--	--	--

<p>during the manufacture of the finished product - Other variation</p> <p>B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits</p> <p>B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits</p> <p>B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation</p> <p>B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation</p> <p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p> <p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p> <p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p> <p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p>				
---	--	--	--	--

	<p>B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)</p> <p>B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product</p> <p>B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method</p>				
II/0001/G	<p>This was an application for a group of variations.</p> <p>Change to the specifications of the finished product and deletion and update to test methods.</p>	22/09/2011	22/05/2012		

	<p>B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product</p> <p>B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p>				
II/0004/G	<p>This was an application for a group of variations.</p> <p>-The SmPC is proposed to be updated in section 4.9 to provide more information regarding handling of suspected overdose, and in section 5.2 to provide information about the biphasic elimination of rotigotine. In addition, section 4.8 has been updated to precise the study data base used for the ADR table, and a statement on the post-marketing experience is added. The patient leaflet is amended for overdose handling in section 3, and involuntary movements and convulsions are added as likely side effects caused by overdosing in this section. Annex II has been amended to be in line with the current QRD template.</p> <p>-Section 5.1 of the SmPC is proposed to be updated to provide a more precise description of rotigotine activity at dopamine and 5-HT1A receptors, and to provide more information regarding the mode of action for the treatment of Restless Legs Syndrome. An editorial change has been made in section 4.4 to</p>	17/11/2011	09/01/2012	SmPC, Annex II and PL	<p>The SmPC has been updated in section 5.2 to provide information about the biphasic elimination of rotigotine based on two clinical pharmacology studies which verify that a two compartment model would fit the concentrations obtained after patch removal. Section 4.9 has been amended to provide more information regarding handling of suspected overdose, and the PL has been updated accordingly. Section 4.8 has been updated to precise the study data base used for the ADR table, and a statement on the post-marketing experience has been added.</p> <p>Section 5.1 of the SmPC has been amended to provide a more precise description of the rotigotine activity and mechanism of action for rotigotine in regards to dopamine and 5HTA1 receptors, and information with regard to the mode of action of rotigotine as a treatment of Restless Legs Syndrome (RLS) has been added.</p> <p>The MAH conducted a Phase 3, double-blind, placebo-controlled, 2-arm trial of rotigotine in 287 subjects with early-stage or advanced-stage idiopathic Parkinson's disease. A statistically significant improvement was seen in</p>

	<p>delete a double wording.</p> <p>-Section 5.1 of the SPC is proposed to be updated to include new clinical data from a phase 3 study to evaluate the effect of rotigotine on early morning motor function, sleep quality, nocturnal symptoms and non-motor symptoms in subjects with idiopathic Parkinson's disease.</p> <p>C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data</p> <p>C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data</p> <p>C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data</p>				<p>the co-primary outcome measures early morning motor function, assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) Part III, and nocturnal sleep disturbances, measured by the modified Parkinson's Disease Sleep Scale (PDSS-2). A summary of the most important results from the study has been added to section 5.1.</p>
N/0003	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	14/12/2011	30/08/2012	Labelling and PL	
IG/0129	C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system	09/12/2011	n/a		
IA/0002/G	<p>This was an application for a group of variations.</p> <p>A.1 - Administrative change - Change in the name and/or address of the MAH</p> <p>A.4 - Administrative change - Change in the name</p>	24/08/2011	n/a	SmPC, Annex II, Labelling and PL	

	<p>and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS</p> <p>A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release</p>				
--	--	--	--	--	--